Hawaii 2023 Regular Session

Hawaii Senate Bill SR153

Introduced
3/10/23  

Caption

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

Impact

The establishment of the Therapeutic Psilocybin Working Group will leverage existing research on the efficacy and safety of psilocybin. The group's objectives include reviewing relevant federal, state, and county laws governing the use of psilocybin, as well as analyzing medical and scientific studies related to its therapeutic benefits. Moreover, the group is tasked with developing a strategic plan to ensure the accessibility of psilocybin treatments for adults age 21 and older. Such steps could lead to policy changes that significantly impact mental health treatment in Hawaii, potentially increasing access to innovative therapies for mental health conditions.

Summary

Senate Resolution 153 (SR153) is a legislative measure that requests the Hawaii Department of Health to establish a Therapeutic Psilocybin Working Group. This initiative aims to address the increasing challenges of mental health care in Hawaii, particularly given the shortage of mental health professionals and appropriate treatment options. The resolution highlights the potential of psilocybin, a psychedelic compound found in certain mushrooms, to treat various mental health disorders such as PTSD, depression, and anxiety. The FDA has designated psilocybin treatment for treatment-resistant depression as a 'breakthrough therapy', underscoring its importance in modern therapeutic practices.

Contention

While SR153 seeks to promote innovative therapies for mental health, it may also raise points of contention regarding the legalization and regulation of psilocybin. Some stakeholders may express concerns about the safety, ethical implications, and potential for misuse of psilocybin-based products. Additionally, the bill prompts discussions on how state laws may evolve to accommodate new treatment methodologies that incorporate psychoactive substances. This could fuel debates on public health policies, drug regulations, and the frameworks necessary to safely integrate psilocybin into therapeutic practices.

Companion Bills

HI HR206

Same As Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SCR133

Same As Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

Similar Bills

HI SCR133

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HCR202

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HR206

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SR88

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.

HI HB2400

Relating To Psilocybin.

HI SB3160

Relating To Psilocybin.

HI SCR100

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Long-term Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.

HI SB1454

Relating To Psilocybin.